Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs

被引:0
作者
Carlson, KW
Nawy, SS
Wei, ET
Sadée, W
Filov, VA
Rezsova, VV
Slominski, A
Quillan, JM
机构
[1] Univ Calif San Francisco, Dept Pharmaceut Chem & Biopharmaceut Sci, Sch Pharm, San Francisco, CA 94143 USA
[2] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA
[3] NN Petrov Oncol Res Inst, St Petersburg, Russia
[4] Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA
关键词
corticotropin-releasing hormone; receptor; cell proliferation; metastasis; melanoma; calcium signaling; hypotension; in vivo; in vitro; assay; tumor;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Observations that epidermal cells release both corticotropin-releasing hormone (CRH) and proopiome lanocortin (POMC) peptides has raised questions about the physiological relevance of this hypothalamo-pituitary-like system in mammalian skin. As CRH has shown anti-proliferative effects on cultured keratinocytes, we tested whether CRH can also regulate growth of melanoma cells. Materials and Methods. CRH, [D-Glu(20)]-CRH, [D-Pro(5)]-CRH, acetyl-cyclo(3033)[D-Phe(12),D-Glu(20),Nle(21),D-His(32),Lys(33),D-Nle(38)]-CRH(4-41), acetyl-cyclo(30-33)[D-Phe(12),Nle(18),D-Glu(20),Nle(21),D-Ala(32)]-urotensin 1(4-41), urocortin, and sauvagine were tested on Cloudman melanoma cell proliferation in culture and B16 melanoma tumor growth in C57B1/6 mice. Calcium-sensitive fluorescence measurements were used to examine the effect of CRH on intracellular Ca2+ signaling. The effects of CRH and CRH on intracellular Ca [D-Glu(20)]-CRH on blood pressure were compared by measuring mean arterial pressure in anesthetized rats. Results: CRH and si analogs were tested, and all demonstrated exceptional potency in inhibiting Cloudman cell proliferation in culture, with half-maximal effective concentrations ranging between 0.2 and 100pM. The amplitude of ionomycin-induced Ca2+ influx into Cloudman cells grown in suspension was reduced by 50% after 48-hr exposure to CRH. Daily injections of CRH or [D-Glu(20)]-CRH, 100 mug/kg.day s.c., for 5 days, reduced net B16 tumor volume in mice by 30-60% compared to control animals. [D-Glu(20)]-CRH was less hypotensive compared to CRH, despite having similar anti-proliferative potency. Conclusion: CRH, and various analogs thereof inhibit proliferation of Cloudman cells in culture, and inhibit B16 tumor-growth rate in vivo, most likely by activation of endogenous CRH1 receptors and subsequent altered intracellular Ca2+ signaling. CRH analogs, such as [D-Glu(20)]-CRH, with less hypotensive activity may provide new directions of therapy for melanoma.
引用
收藏
页码:1173 / 1179
页数:7
相关论文
共 44 条
  • [11] Effect of CRF and related peptides on calcium signaling in human and rodent melanoma cells
    Fazal, N
    Slominski, A
    Choudhry, MA
    Wei, ET
    Sayeed, MM
    [J]. FEBS LETTERS, 1998, 435 (2-3): : 187 - 190
  • [12] Expression of proopiomelanocortin, corticotropin-releasing hormone (CRH), and CRH receptor in melanoma cells, nevus cells, and normal human melanocytes
    Funasaka, Y
    Sato, H
    Chakraborty, AK
    Ohashi, A
    Chrousos, GP
    Ichihashi, M
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 1999, 4 (02) : 105 - 109
  • [13] Labelling of CRF1 and CRF2 receptors using the novel radioligand, [H-3]-urocortin
    Gottowik, J
    Goetschy, V
    Henriot, S
    Kitas, E
    Fluhman, B
    Clerc, RG
    Moreau, JL
    Monsma, FJ
    Kilpatrick, GJ
    [J]. NEUROPHARMACOLOGY, 1997, 36 (10) : 1439 - 1446
  • [14] POTENT, STRUCTURALLY CONSTRAINED AGONISTS AND COMPETITIVE ANTAGONISTS OF CORTICOTROPIN-RELEASING FACTOR
    GULYAS, J
    RIVIER, C
    PERRIN, M
    KOERBER, SC
    SUTTON, S
    CORRIGAN, A
    LAHRICHI, SL
    CRAIG, AG
    VALE, W
    RIVIER, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) : 10575 - 10579
  • [15] HYPOTENSIVE EFFECTS OF OVINE AND HUMAN CORTICOTROPIN-RELEASING FACTORS IN MAN
    HERMUS, ARMM
    PIETERS, GFFM
    WILLEMSEN, JJ
    ROSS, HA
    SMALS, AGH
    BENRAAD, TJ
    KLOPPENBORG, PWC
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 31 (05) : 531 - 534
  • [16] HO RCS, 1995, CANCER, V75, P735, DOI 10.1002/1097-0142(19950115)75:2+<735::AID-CNCR2820751418>3.0.CO
  • [17] 2-Q
  • [18] DESIGN, SYNTHESIS, AND CONFORMATION OF SUPERPOTENT AND PROLONGED ACTING MELANOTROPINS
    HRUBY, VJ
    SHARMA, SD
    TOTH, K
    JAW, JY
    ALOBEIDI, F
    SAWYER, TK
    HADLEY, ME
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, 680 : 51 - 63
  • [19] KIANG JG, 1987, J PHARMACOL EXP THER, V243, P517
  • [20] Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges
    Koerber, SC
    Gulyas, J
    Lahrichi, SL
    Corrigan, A
    Craig, AG
    Rivier, C
    Vale, W
    Rivier, J
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (25) : 5002 - 5011